Maroof Alam

List of Publications by Citations

29 papers	1,220 citations	24 h-index	29 g-index
29 ext. papers	1,469 ext. citations	7.1 avg, IF	4.04 L-index

#	Paper	IF	Citations
29	Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. *Molecular Cancer Therapeutics*, **2011**, 10, 806-16	6.1	124
28	MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. *Cancer Research*, **2018**, 78, 205-215	10.1	89
27	Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. *Oncotarget*, **2016**, 7, 11756-69	3.3	83
26	MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. *Science Signaling*, **2011**, 4, ra9	8.8	66
25	MUC1-C oncoprotein activates ERK-γ/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. *Journal of Biological Chemistry*, **2013**, 288, 30892-903	5.4	61
24	MUC1-C drives MYC in multiple myeloma. *Blood*, **2016**, 127, 2587-97	2.2	60
23	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. *Cancer Research*, **2016**, 76, 1538-48	10.1	59
22	MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. *Journal of Biological Chemistry*, **2012**, 287, 10703-10713	5.4	55
21	Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. *Oncotarget*, **2014**, 5, 2622-34	3.3	53
20	MUC1-C Induces the LIN28B-LET-7-HMGA2 Axis to Regulate Self-Renewal in NSCLC. *Molecular Cancer Research*, **2015**, 13, 449-60	6.6	48
19	MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. *Oncotarget*, **2014**, 5, 8893-905	3.3	48
18	The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. *Journal of Biological Chemistry*, **2012**, 287, 20866-75	5.4	41
17	Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2013**, 9, 247-56	6	39
16	MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. *Prostate*, **2012**, 72, 1659-68	4.2	39
15	MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. *PLoS ONE*, **2011**, 6, e28234	3.7	39
14	Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. *Clinical Cancer Research*, **2015**, 21, 2338-47	12.9	37
13	Potential of diallyl sulfide bearing pH-sensitive liposomes in chemoprevention against DMBA-induced skin papilloma. *Molecular Medicine*, **2007**, 13, 443-51	6.2	33

List of Publications

12	Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. *Molecular Cancer*, **2017**, 16, 33	42.1	32
11	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. *Oncotarget*, **2016**, 7, 38974-38987	3.3	32
10	MUC1-C activates EZH2 expression and function in human cancer cells. *Scientific Reports*, **2017**, 7, 7481	4.9	29
9	MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. *Scientific Reports*, **2016**, 6, 26643	4.9	29
8	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. *OncoImmunology*, **2017**, 6, e1338998	7.2	28
7	MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. *Molecular Cancer Research*, **2016**, 14, 1266-1276	6.6	26
6	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. *Blood*, **2015**, 126, 354-62	2.2	25
5	Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. *Signal Transduction and Targeted Therapy*, **2018**, 3, 13	21	20
4	Efficacy of niosomal formulation of diallyl sulfide against experimental candidiasis in Swiss albino mice. *Nanomedicine*, **2009**, 4, 713-24	5.6	19
3	Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. *Oncotarget*, **2017**, 8, 69237-69249	3.3	5
2	Use of a Liposomal Delivery System for Herbal-Based Therapeutics (with a Focus on Clove Oil)357-367		1
1	MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. *Blood*, **2014**, 124, 808-808	2.2	